Policy & Advocacy

ASGCT Holds First Joint Meeting With Brazilian Association

ASGCT Staff - December 03, 2020

Speakers addressed the scientific and infrastructural requirements for successful translation into clinical research for oncology, hemophilia, and sickle cell disease.

ASGCT held its first ever collaborative event with the Brazilian Association of Cellular and Gene Therapy (ABTCel-Gen) virtually Dec. 2. Academic researchers from Brazil and the U.S. shared their experiences in establishing clinical trials for gene therapies to assist in advancing further development within Brazil. The ASGCT Global Outreach Committee co-hosted this program as part of its objective to encourage clinical development in middle-income countries that have burgeoning regulatory frameworks and medical systems that can support gene therapy. By facilitating the development and approval of more therapies globally, such events contribute to the Society’s strategic goal to foster equitable access to gene and cell therapies in low- and middle-income countries.

Speakers addressed the scientific and infrastructural requirements for successful translation into clinical research for oncology, hemophilia, and sickle cell disease. In addition, ASGCT Board Member Maritza McIntyre, Ph.D., provided recommendations on information to include in an IND application and ways to overcome common regulatory challenges in gene therapy trials. A recording of the program is available below. The Society will continue to partner with ABTCel-Gen when ASGCT members speak on gene editing at ABTCel-Gen’s virtual annual meeting in April.

Related Articles

Policy & Advocacy

ASGCT Responds to FDA’s Advanced Manufacturing Technologies Designation Program Draft Guidance

Margarita L. Valdez Martínez - March 11, 2024
ASGCT-FDA Liaison Meeting

ASGCT Members Share Regulatory Recommendations During FDA Liaison Meeting

Christina Mayer, MPA - March 07, 2024
ASGCT News

Dr. Terence Flotte Calls for CGT Investment and Collaboration During Congressional Testimony

Read Dr. Flotte's testimony + watch the hearing - February 29, 2024
Policy & Advocacy

Final FDA Guidances on Gene Editing + CAR T-Cell Products Include Society Recommendations

Christina Mayer, MPA - February 28, 2024